A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorSichuan Baili Pharmaceutical Co., Ltd.
About this trial
This study is a phase II clinical study to explore the efficacy and safety of BL-B01D1 + PD-1 monoclonal antibody combination therapy in patients with extensive-stage small cell lung cancer.
Eligibility criteria
Qualifiers
Subject volunteered to participate in the study and signed an informed consent;
Male or female aged ≥18 years and ≤75 years;
Expected survival time ≥3 months;
ECOG score 0-1;
Disqualifiers
Prior use of ADC drug therapy with small molecule toxins as topoisomerase I inhibitors;
Prior treatment with any systemic anti-tumor regimen for extensive-stage small cell lung cancer;
Pathology suggested small cell carcinoma containing non-small cell carcinoma components;
Subjects had used immunomodulatory drugs within 14 days before the first use of the study drug ;
Trial design
Treatments tested in this trial
- BL-B01D1
- PD-1 monoclonal antibody
Treatment groups
66 Participants
are divided into 1 treatment groupSponsors and collaborators
Sichuan Baili Pharmaceutical Co., Ltd.
Lead sponsor
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Collaborator
Source ClinicalTrials.gov